Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resista...
Uloženo v:
| Vydáno v: | The Lancet (British edition) Ročník 382; číslo 9893; s. 700 - 708 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
Elsevier Ltd
24.08.2013
Elsevier Limited |
| Témata: | |
| ISSN: | 0140-6736, 1474-547X, 1474-547X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance.
ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1:1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered at ClinicalTrials.gov, NCT01231516.
Analysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7·4%, 95% CI 0·7 to 14·2); superiority of dolutegravir versus raltegravir was then concluded (p=0·03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (four vs 17 patients; adjusted difference −3·7%, 95% CI −6·1 to −1·2; p=0·003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%] vs 64 [18%] patients), upper respiratory tract infection (38 [11%] vs 29 [8%]), and headache (33 [9%] vs 31 [9%]). Safety events leading to discontinuation were infrequent in both groups (nine [3%] dolutegravir, 14 [4%] raltegravir).
Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group.
ViiV Healthcare. |
|---|---|
| AbstractList | Summary Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance. Methods ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1:1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered at ClinicalTrials.gov , NCT01231516. Findings Analysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7·4%, 95% CI 0·7 to 14·2); superiority of dolutegravir versus raltegravir was then concluded (p=0·03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (four vs 17 patients; adjusted difference −3·7%, 95% CI −6·1 to −1·2; p=0·003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%] vs 64 [18%] patients), upper respiratory tract infection (38 [11%] vs 29 [8%]), and headache (33 [9%] vs 31 [9%]). Safety events leading to discontinuation were infrequent in both groups (nine [3%] dolutegravir, 14 [4%] raltegravir). Interpretation Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group. Funding ViiV Healthcare. Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance. ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1:1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered at ClinicalTrials.gov, NCT01231516. Analysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7·4%, 95% CI 0·7 to 14·2); superiority of dolutegravir versus raltegravir was then concluded (p=0·03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (four vs 17 patients; adjusted difference −3·7%, 95% CI −6·1 to −1·2; p=0·003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%] vs 64 [18%] patients), upper respiratory tract infection (38 [11%] vs 29 [8%]), and headache (33 [9%] vs 31 [9%]). Safety events leading to discontinuation were infrequent in both groups (nine [3%] dolutegravir, 14 [4%] raltegravir). Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group. ViiV Healthcare. Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance. Methods ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1:1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered atClinicalTrials.gov,NCT01231516. Findings Analysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7·4%, 95% CI 0·7 to 14·2); superiority of dolutegravir versus raltegravir was then concluded (p=0·03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (fourvs17 patients; adjusted difference ?3·7%, 95% CI ?6·1 to ?1·2; p=0·003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%]vs64 [18%] patients), upper respiratory tract infection (38 [11%]vs29 [8%]), and headache (33 [9%]vs31 [9%]). Safety events leading to discontinuation were infrequent in both groups (nine [3%] dolutegravir, 14 [4%] raltegravir). Interpretation Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group. Funding ViiV Healthcare. BACKGROUND: Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance. METHODS: ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1:1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered at ClinicalTrials.gov, NCT01231516. FINDINGS: Analysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7·4%, 95% CI 0·7 to 14·2); superiority of dolutegravir versus raltegravir was then concluded (p=0·03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (four vs 17 patients; adjusted difference −3·7%, 95% CI −6·1 to −1·2; p=0·003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%] vs 64 [18%] patients), upper respiratory tract infection (38 [11%] vs 29 [8%]), and headache (33 [9%] vs 31 [9%]). Safety events leading to discontinuation were infrequent in both groups (nine [3%] dolutegravir, 14 [4%] raltegravir). INTERPRETATION: Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group. FUNDING: ViiV Healthcare. Background: Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance. Methods: ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1:1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered at ClinicalTrials.gov, NCT01231516. Findings: Analysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7.4%, 95% CI 0.7 to 14.2); superiority of dolutegravir versus raltegravir was then concluded (p=0.03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (four vs 17 patients; adjusted difference -3.7%, 95% CI -6.1 to -1.2; p=0.003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%] vs 64 [18%] patients), upper respiratory tract infection (38 [11%] vs 29 [8%]), and headache (33 [9%] vs 31 [9%]). Safety events leading to discontinuation were infrequent in both groups (nine [3%] dolutegravir, 14 [4%] raltegravir). Interpretation: Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group. Funding ViiV Healthcare. Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance.BACKGROUNDDolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance.ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1:1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered at ClinicalTrials.gov, NCT01231516.METHODSING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1:1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered at ClinicalTrials.gov, NCT01231516.Analysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7·4%, 95% CI 0·7 to 14·2); superiority of dolutegravir versus raltegravir was then concluded (p=0·03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (four vs 17 patients; adjusted difference -3·7%, 95% CI -6·1 to -1·2; p=0·003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%] vs 64 [18%] patients), upper respiratory tract infection (38 [11%] vs 29 [8%]), and headache (33 [9%] vs 31 [9%]). Safety events leading to discontinuation were infrequent in both groups (nine [3%] dolutegravir, 14 [4%] raltegravir).FINDINGSAnalysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7·4%, 95% CI 0·7 to 14·2); superiority of dolutegravir versus raltegravir was then concluded (p=0·03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (four vs 17 patients; adjusted difference -3·7%, 95% CI -6·1 to -1·2; p=0·003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%] vs 64 [18%] patients), upper respiratory tract infection (38 [11%] vs 29 [8%]), and headache (33 [9%] vs 31 [9%]). Safety events leading to discontinuation were infrequent in both groups (nine [3%] dolutegravir, 14 [4%] raltegravir).Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group.INTERPRETATIONOnce-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group.ViiV Healthcare.FUNDINGViiV Healthcare. Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance. ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1:1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered at ClinicalTrials.gov, NCT01231516. Analysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7·4%, 95% CI 0·7 to 14·2); superiority of dolutegravir versus raltegravir was then concluded (p=0·03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (four vs 17 patients; adjusted difference -3·7%, 95% CI -6·1 to -1·2; p=0·003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%] vs 64 [18%] patients), upper respiratory tract infection (38 [11%] vs 29 [8%]), and headache (33 [9%] vs 31 [9%]). Safety events leading to discontinuation were infrequent in both groups (nine [3%] dolutegravir, 14 [4%] raltegravir). Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group. ViiV Healthcare. Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance. Methods ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1:1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered at ClinicalTrials.gov, NCT01231516. Findings Analysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7 times 4%, 95% CI 0 times 7 to 14 times 2); superiority of dolutegravir versus raltegravir was then concluded (p=0 times 03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (four 17 patients; adjusted difference -3 times 7%, 95% CI -6 times 1 to -1 times 2; p=0 times 003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%] 64 [18%] patients), upper respiratory tract infection (38 [11%] 29 [8%]), and headache (33 [9%] 31 [9%]). Safety events leading to discontinuation were infrequent in both groups (nine [3%] dolutegravir, 14 [4%] raltegravir). Interpretation Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group. Funding ViiV Healthcare. |
| Author | Brites, Carlos Min, Sherene Mingrone, Horacio Madruga, Jose Lombaard, John Andrade-Villanueva, Jaime F Underwood, Mark Buendia, Carlos Beltran Pozniak, Anton L Griffith, Sandy Hagins, Debbie Small, Catherine B Felizarta, Franco Newman, Tamara Ramgopal, Moti Fourie, Jan Dorey, David Shuldyakov, Andrey Cahn, Pedro Richmond, Gary Grinsztejn, Beatriz Reuter, Tania |
| Author_xml | – sequence: 1 givenname: Pedro surname: Cahn fullname: Cahn, Pedro email: pcahn@huesped.org.ar organization: Fundacion Huesped, Buenos Aires, Argentina – sequence: 2 givenname: Anton L surname: Pozniak fullname: Pozniak, Anton L organization: Chelsea and Westminster Hospital NHS Foundation Trust, London, UK – sequence: 3 givenname: Horacio surname: Mingrone fullname: Mingrone, Horacio organization: Fundacion IDEAA, Buenos Aires, Argentina – sequence: 4 givenname: Andrey surname: Shuldyakov fullname: Shuldyakov, Andrey organization: Saratov Regional Centre of Prophylactic AIDS, Saratov, Russia – sequence: 5 givenname: Carlos surname: Brites fullname: Brites, Carlos organization: Complexo Hospitalar Prof Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil – sequence: 6 givenname: Jaime F surname: Andrade-Villanueva fullname: Andrade-Villanueva, Jaime F organization: Hospital Civil de Guadalajara, “Fray Antonio Alcalde” CUCS, Universidad de Guadalajara, Guadalajara, Mexico – sequence: 7 givenname: Gary surname: Richmond fullname: Richmond, Gary organization: Broward Health Medical Center, Fort Lauderdale, FL, USA – sequence: 8 givenname: Carlos Beltran surname: Buendia fullname: Buendia, Carlos Beltran organization: Hospital Barros Luco Trudeau, Santiago, Chile – sequence: 9 givenname: Jan surname: Fourie fullname: Fourie, Jan organization: Fourie Medical Centre, Dundee, South Africa – sequence: 10 givenname: Moti surname: Ramgopal fullname: Ramgopal, Moti organization: Midway Immunology and Research Center, Fort Pierce, FL, USA – sequence: 11 givenname: Debbie surname: Hagins fullname: Hagins, Debbie organization: Chatham CARE Center, Savannah, GA, USA – sequence: 12 givenname: Franco surname: Felizarta fullname: Felizarta, Franco organization: Private practice, Bakersville, CA, USA – sequence: 13 givenname: Jose surname: Madruga fullname: Madruga, Jose organization: Centro de Referencia e Treinamento DST/AIDS, São Paulo, Brazil – sequence: 14 givenname: Tania surname: Reuter fullname: Reuter, Tania organization: Universidade Federal do Espirito Santo, Vitoria, Brazil – sequence: 15 givenname: Tamara surname: Newman fullname: Newman, Tamara organization: Instituto de Infectologia Emilio Ribas, São Paulo, Brazil – sequence: 16 givenname: Catherine B surname: Small fullname: Small, Catherine B organization: New York Medical College, Valhalla, NY, USA – sequence: 17 givenname: John surname: Lombaard fullname: Lombaard, John organization: JOSHA Research, Bloemfontein, South Africa – sequence: 18 givenname: Beatriz surname: Grinsztejn fullname: Grinsztejn, Beatriz organization: Inst de Pesquisa Clinica Evandro Chagas Fiocruz, Rio de Janeiro, Brazil – sequence: 19 givenname: David surname: Dorey fullname: Dorey, David organization: GlaxoSmithKline, Mississauga, ON, Canada – sequence: 20 givenname: Mark surname: Underwood fullname: Underwood, Mark organization: GlaxoSmithKline, Research Triangle Park, NC, USA – sequence: 21 givenname: Sandy surname: Griffith fullname: Griffith, Sandy organization: GlaxoSmithKline, Research Triangle Park, NC, USA – sequence: 22 givenname: Sherene surname: Min fullname: Min, Sherene organization: GlaxoSmithKline, Research Triangle Park, NC, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23830355$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkt9u0zAUhyM0xLrBIwCRuBkSAf-JnQQEaBqwVargogxxZznOyeYttYvtdPTVeDqcdhtSJdReRY6_851j-3eQ7BlrIEmeYvQaI8zfTBHOUcYLyo8wfckxIThDD5IRzos8Y3nxcy8Z3SP7yYH3VwihnCP2KNkntKSIMjZK_nyyXR_gwsmFdukCnO996mR3_0ubVJqgHQRn41p2Gfyeg9NgFDSv4vaK9JBpc6lrHazLjNQLSGXTd8GnNzpcpmfjH2_TG4DrNC9TB3610zo7S8MlxHamsTPtB19j-7qDrO60iat45uhtYzvrdFim0-PxZPz1NPWhb5aPk4et7Dw8uf0eJudfPn8_Ocsm307HJ8eTTHHCQoZzjBSpVNUgWksMrMZIKlniEji0hElVK1VhWbMWFYBpzUkFgNuqJaWiFaGHydHaO3f2Vw8-iDirgq6TBmzvBeZFyWiFCN-OMs5LVlZsBzSPvaOaVTugpCQFyssioi820CvbOxOvZ6AKijEvUaSe3VJ9PYNGzJ2eSbcUd7GIwLs1oJz13kErlA4yaGuCk7oTGIkhhGIVQjEkTGAqViEUg55tVN812Fb3fF3XSivkhdNenE8JwgwhHOfKaSQ-rgmI773Q4IRX6yTGgKogGqu39viwYVAxalrJ7hqW4P_dlvBEoLVkcGC6MgyC9_8X7DDAX7h8Jjw |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1128_aac_01751_21 crossref_primary_10_1097_MD_0000000000014828 crossref_primary_10_1128_AAC_01235_13 crossref_primary_10_1177_09564624211027099 crossref_primary_10_1093_jac_dkv012 crossref_primary_10_1093_jac_dkw109 crossref_primary_10_1097_QAI_0000000000003571 crossref_primary_10_1002_jcph_6128 crossref_primary_10_1111_bcpt_12828 crossref_primary_10_1093_jac_dkw464 crossref_primary_10_1155_2021_5567332 crossref_primary_10_1016_j_idnow_2021_12_005 crossref_primary_10_1093_cid_ciy228 crossref_primary_10_1016_j_coviro_2014_07_006 crossref_primary_10_1097_QAD_0000000000001494 crossref_primary_10_3389_fcimb_2023_1187999 crossref_primary_10_1093_jac_dkae085 crossref_primary_10_3390_v7072790 crossref_primary_10_1097_01_JAA_0000475465_07971_19 crossref_primary_10_1128_AAC_00539_19 crossref_primary_10_1016_j_ijantimicag_2019_08_008 crossref_primary_10_1093_jac_dkv243 crossref_primary_10_1089_aid_2020_0242 crossref_primary_10_1007_s40121_016_0126_x crossref_primary_10_1007_s40267_015_0226_9 crossref_primary_10_1093_jac_dkw571 crossref_primary_10_1007_s40262_016_0424_1 crossref_primary_10_1093_cid_ciz684 crossref_primary_10_1007_s40506_019_00203_7 crossref_primary_10_1371_journal_pone_0223464 crossref_primary_10_3390_v10010041 crossref_primary_10_1097_QAI_0000000000001269 crossref_primary_10_1097_COH_0000000000000445 crossref_primary_10_1111_hiv_12468 crossref_primary_10_3390_v15102083 crossref_primary_10_1093_jac_dku144 crossref_primary_10_1007_s40121_024_01085_z crossref_primary_10_1080_09540121_2021_1923631 crossref_primary_10_1093_infdis_jiy176 crossref_primary_10_1093_infdis_jiy175 crossref_primary_10_1080_14740338_2020_1764531 crossref_primary_10_1136_ejhpharm_2020_002374 crossref_primary_10_1097_QAD_0000000000001279 crossref_primary_10_1097_QAD_0000000000003695 crossref_primary_10_1007_s40121_021_00522_7 crossref_primary_10_1371_journal_pone_0222229 crossref_primary_10_1089_aid_2020_0022 crossref_primary_10_1093_cid_ciaf135 crossref_primary_10_1177_0956462418816785 crossref_primary_10_1517_14740338_2015_1059818 crossref_primary_10_1093_infdis_jiy186 crossref_primary_10_1177_8755122514544126 crossref_primary_10_1016_S2352_3018_18_30040_7 crossref_primary_10_1371_journal_pone_0147821 crossref_primary_10_1093_cid_cix1083 crossref_primary_10_1371_journal_pone_0145885 crossref_primary_10_1097_FPC_0000000000000308 crossref_primary_10_1097_QAD_0000000000000199 crossref_primary_10_1097_QAI_0000000000002454 crossref_primary_10_1007_s11481_020_09907_w crossref_primary_10_1093_infdis_jiz281 crossref_primary_10_1016_S2352_3018_22_00044_3 crossref_primary_10_1080_14656566_2022_2029409 crossref_primary_10_1016_S1473_3099_19_30036_2 crossref_primary_10_7448_IAS_18_1_20824 crossref_primary_10_1177_0956462416679550 crossref_primary_10_1002_cpt_3370 crossref_primary_10_1177_0049475520953704 crossref_primary_10_1371_journal_pone_0077448 crossref_primary_10_7326_M18_3358 crossref_primary_10_3390_genes12091314 crossref_primary_10_1136_sextrans_2020_054821 crossref_primary_10_1016_j_heliyon_2023_e23072 crossref_primary_10_1080_14787210_2020_1729742 crossref_primary_10_1097_QAI_0000000000003400 crossref_primary_10_1517_14740338_2014_897327 crossref_primary_10_1097_QAD_0000000000001191 crossref_primary_10_1093_jac_dkv430 crossref_primary_10_1089_aid_2021_0140 crossref_primary_10_1128_AAC_03909_14 crossref_primary_10_4103_cmrp_cmrp_98_23 crossref_primary_10_1016_j_virusres_2016_07_006 crossref_primary_10_1517_17425255_2015_1056732 crossref_primary_10_1177_2042098618798350 crossref_primary_10_1093_cid_ciz372 crossref_primary_10_1517_14656566_2014_913023 crossref_primary_10_4102_sajhivmed_v21i1_1115 crossref_primary_10_1007_s40121_014_0024_z crossref_primary_10_1517_14656566_2015_1044436 crossref_primary_10_7759_cureus_30556 crossref_primary_10_1080_14656566_2019_1612364 crossref_primary_10_1007_s15010_021_01668_9 crossref_primary_10_1097_QAD_0000000000001194 crossref_primary_10_1093_cid_ciae127 crossref_primary_10_1177_09564624221146608 crossref_primary_10_1586_14787210_2014_907525 crossref_primary_10_1093_cid_ciae125 crossref_primary_10_1128_AAC_04844_14 crossref_primary_10_11604_pamj_2024_47_137_40726 crossref_primary_10_1186_s12977_018_0420_7 crossref_primary_10_1007_s11904_019_00480_3 crossref_primary_10_1007_s00228_013_1590_9 crossref_primary_10_1177_0956462416688127 crossref_primary_10_1093_jpids_piy139 crossref_primary_10_1186_s12977_016_0265_x crossref_primary_10_3390_v15040822 crossref_primary_10_1128_JVI_03353_14 crossref_primary_10_1128_JVI_01189_18 crossref_primary_10_3390_ph15121533 crossref_primary_10_1093_jac_dkw504 crossref_primary_10_3390_v6072858 crossref_primary_10_1089_aid_2020_0196 crossref_primary_10_1089_aid_2018_0117 crossref_primary_10_1093_ofid_ofab648 crossref_primary_10_1016_j_ijantimicag_2018_01_009 crossref_primary_10_1007_s40265_020_01379_9 crossref_primary_10_1093_ofid_ofaa202 crossref_primary_10_1007_s40265_015_0515_6 crossref_primary_10_1073_pnas_1820333116 crossref_primary_10_2147_HIV_S316776 crossref_primary_10_1007_s40121_013_0020_8 crossref_primary_10_1016_S2352_3018_19_30146_8 crossref_primary_10_1016_S2352_3018_22_00163_1 crossref_primary_10_1016_S0140_6736_23_01381_8 crossref_primary_10_3390_v6104095 crossref_primary_10_1007_s40265_015_0361_6 crossref_primary_10_1093_ndt_gfw064 crossref_primary_10_1093_cid_ciu834 crossref_primary_10_1128_JVI_02131_15 crossref_primary_10_1007_s00228_014_1732_8 crossref_primary_10_1089_aid_2017_0184 crossref_primary_10_1097_QAI_0000000000002075 crossref_primary_10_1371_journal_pone_0181357 crossref_primary_10_1186_s12879_018_3042_8 crossref_primary_10_1016_S1473_3099_13_70257_3 crossref_primary_10_1093_jac_dku439 crossref_primary_10_2217_fvl_2019_0077 crossref_primary_10_2217_fvl_14_80 crossref_primary_10_3109_07853890_2014_883169 crossref_primary_10_1111_bcp_12428 crossref_primary_10_1097_MD_0000000000016721 crossref_primary_10_1371_journal_pone_0160087 crossref_primary_10_1097_QAD_0000000000002194 crossref_primary_10_1016_j_jcv_2018_06_012 crossref_primary_10_1097_COH_0000000000000011 crossref_primary_10_7554_eLife_46344 crossref_primary_10_1016_j_cplett_2018_09_019 crossref_primary_10_3390_v16030399 crossref_primary_10_1093_jac_dku424 crossref_primary_10_2147_RRTM_S341711 crossref_primary_10_3390_v14010163 crossref_primary_10_1080_14656566_2016_1232387 crossref_primary_10_1080_14656566_2018_1450866 crossref_primary_10_1186_s13643_022_02102_3 crossref_primary_10_1016_j_antiviral_2022_105427 crossref_primary_10_1093_jac_dku535 crossref_primary_10_1093_ofid_ofaa404 crossref_primary_10_1093_ofid_ofz060 crossref_primary_10_2174_0929867328666210708090123 crossref_primary_10_2174_0118746136382073250806110823 crossref_primary_10_1007_s12325_021_01842_3 crossref_primary_10_2217_fvl_14_68 crossref_primary_10_1097_COH_0000000000000388 crossref_primary_10_1093_cid_ciae557 crossref_primary_10_1371_journal_pone_0144917 crossref_primary_10_2147_IMCRJ_S323233 crossref_primary_10_1128_AAC_04274_14 crossref_primary_10_3390_ijms21051553 crossref_primary_10_1097_01_NPR_0000444657_88872_7f crossref_primary_10_1016_j_nmni_2015_02_003 crossref_primary_10_1080_09540121_2021_1916873 crossref_primary_10_1111_bcp_12639 crossref_primary_10_1177_2040622314530461 crossref_primary_10_1097_MD_0000000000023335 crossref_primary_10_1016_S2352_3018_23_00228_X crossref_primary_10_3390_v6093487 crossref_primary_10_3390_pharmaceutics13111798 crossref_primary_10_1016_j_jmsacl_2024_09_001 crossref_primary_10_1016_j_ijid_2021_03_018 crossref_primary_10_1016_S0140_6736_13_61456_7 crossref_primary_10_1128_AAC_02533_18 crossref_primary_10_1093_infdis_jix398 crossref_primary_10_1074_jbc_REV119_006901 crossref_primary_10_1016_j_meegid_2016_06_047 crossref_primary_10_1093_jac_dkac259 crossref_primary_10_1093_jac_dkz099 crossref_primary_10_1093_jac_dkad101 crossref_primary_10_12688_f1000research_9954_1 crossref_primary_10_1097_QAI_0000000000002035 crossref_primary_10_1155_2014_803185 crossref_primary_10_3390_v6093377 crossref_primary_10_1089_aid_2019_0171 crossref_primary_10_5582_bst_2017_01194 crossref_primary_10_1016_j_jpba_2017_07_003 crossref_primary_10_1016_S1473_3099_14_70736_4 crossref_primary_10_1128_AAC_01474_16 crossref_primary_10_1177_2049936117718101 crossref_primary_10_1093_cid_ciy1095 crossref_primary_10_2147_HIV_S430310 crossref_primary_10_1097_INF_0000000000002577 crossref_primary_10_1007_s13365_020_00874_9 crossref_primary_10_1128_AAC_05181_14 crossref_primary_10_1128_JVI_01725_15 crossref_primary_10_1097_QAD_0000000000001903 crossref_primary_10_1586_14787210_2015_1075393 crossref_primary_10_1186_s12981_022_00499_4 crossref_primary_10_1056_NEJMoa1215541 crossref_primary_10_1080_14737167_2017_1359542 crossref_primary_10_2217_imt_2023_0011 crossref_primary_10_3390_ijms161125957 crossref_primary_10_1186_s12967_021_03120_w crossref_primary_10_1097_QAD_0000000000003098 crossref_primary_10_1093_infdis_jix293 crossref_primary_10_1097_QAI_0000000000002250 crossref_primary_10_1128_AAC_01695_17 crossref_primary_10_1080_17512433_2020_1782737 crossref_primary_10_1097_QAD_0000000000001919 crossref_primary_10_1186_1742_4690_11_7 crossref_primary_10_1093_ofid_ofac628 crossref_primary_10_1097_COH_0000000000000466 crossref_primary_10_1097_INF_0000000000003647 crossref_primary_10_1080_14656566_2018_1560423 crossref_primary_10_1186_s12879_023_08288_8 crossref_primary_10_1097_QAI_0000000000000983 crossref_primary_10_1080_14787210_2018_1544491 crossref_primary_10_1007_s40262_023_01289_5 crossref_primary_10_1016_S2352_3018_17_30095_4 crossref_primary_10_1177_1060028019896638 crossref_primary_10_1371_journal_pone_0162775 crossref_primary_10_1093_infdis_jiaf461 crossref_primary_10_1097_QAD_0000000000000606 crossref_primary_10_1126_science_1248707 crossref_primary_10_1128_AAC_01035_18 crossref_primary_10_1517_14740338_2015_973845 crossref_primary_10_1016_j_jval_2022_12_011 crossref_primary_10_1093_ofid_ofz330 crossref_primary_10_1517_14656566_2014_863277 crossref_primary_10_3851_IMP2878 crossref_primary_10_1371_journal_pone_0307003 crossref_primary_10_1016_j_idc_2014_06_005 crossref_primary_10_1016_S2352_3018_20_30189_2 crossref_primary_10_1097_QAD_0000000000000866 crossref_primary_10_1016_j_jgar_2019_07_015 crossref_primary_10_3390_v16040604 crossref_primary_10_1371_journal_pone_0172206 crossref_primary_10_1097_MD_0000000000016235 crossref_primary_10_1007_s40121_014_0029_7 crossref_primary_10_1007_s40261_018_0739_9 crossref_primary_10_1186_s12879_025_10858_x crossref_primary_10_1097_MD_0000000000005465 crossref_primary_10_1128_AAC_02096_15 crossref_primary_10_1128_AAC_00315_17 crossref_primary_10_1093_ofid_ofac304 crossref_primary_10_1097_QAD_0000000000001845 crossref_primary_10_1097_QAD_0000000000001725 crossref_primary_10_1097_QAD_0000000000000752 crossref_primary_10_3390_ph13060122 crossref_primary_10_1089_apc_2021_0089 crossref_primary_10_1186_1741_7015_11_249 crossref_primary_10_1007_s40261_014_0266_2 crossref_primary_10_1007_s11262_019_01649_z crossref_primary_10_1186_s12879_016_1629_5 crossref_primary_10_1093_cid_ciu221 crossref_primary_10_1093_jac_dkz256 crossref_primary_10_1080_03007995_2023_2189855 crossref_primary_10_1089_aid_2018_0272 crossref_primary_10_1093_jac_dkz021 crossref_primary_10_1016_S2352_3018_22_00094_7 crossref_primary_10_1007_s40267_021_00847_w crossref_primary_10_3390_v13020205 crossref_primary_10_1177_0956462419863925 crossref_primary_10_4103_CIDS_CIDS_20_24 crossref_primary_10_1177_2050313X221079444 crossref_primary_10_1093_jac_dkx195 crossref_primary_10_1093_jac_dkaa471 crossref_primary_10_1177_0956462416651528 crossref_primary_10_1016_j_jcv_2015_07_311 crossref_primary_10_1016_j_chom_2019_06_010 crossref_primary_10_1517_14656566_2014_868884 crossref_primary_10_1093_infdis_jiu051 crossref_primary_10_1517_14656566_2014_868883 crossref_primary_10_4102_sajhivmed_v23i1_1398 crossref_primary_10_1093_ofid_ofy332 crossref_primary_10_1016_S1473_3099_18_30710_2 crossref_primary_10_1093_jac_dkw078 crossref_primary_10_1093_jac_dky497 crossref_primary_10_1093_ofid_ofac107 crossref_primary_10_3390_ph15050587 crossref_primary_10_3390_v15091932 crossref_primary_10_1056_NEJMct1215532 crossref_primary_10_1016_j_eimce_2020_02_009 crossref_primary_10_1016_j_ijantimicag_2024_107294 crossref_primary_10_1155_2021_9384663 crossref_primary_10_1080_14656566_2019_1570131 crossref_primary_10_1093_jac_dkw186 crossref_primary_10_1136_bmjopen_2019_029960 crossref_primary_10_1177_1060028013513558 crossref_primary_10_1186_s12977_018_0440_3 crossref_primary_10_1016_S2352_3018_21_00292_7 crossref_primary_10_1111_biom_12388 crossref_primary_10_1080_14740338_2018_1411903 crossref_primary_10_1097_QAD_0000000000001890 crossref_primary_10_1124_jpet_119_264424 crossref_primary_10_1111_hiv_12510 crossref_primary_10_1111_hiv_12752 crossref_primary_10_3390_v16071162 crossref_primary_10_1097_QAI_0000000000002888 crossref_primary_10_1128_aac_01702_21 crossref_primary_10_1128_AAC_03282_14 crossref_primary_10_1038_s43856_025_00875_x crossref_primary_10_1093_cid_civ124 crossref_primary_10_1007_s40265_014_0256_y crossref_primary_10_3851_IMP3319 crossref_primary_10_1097_QAI_0000000000000698 crossref_primary_10_4102_sajhivmed_v21i1_1062 crossref_primary_10_1007_s40265_025_02181_1 crossref_primary_10_1016_j_ijantimicag_2021_106343 crossref_primary_10_1111_hiv_12506 crossref_primary_10_1002_jia2_25227 crossref_primary_10_3390_v14051028 crossref_primary_10_1111_hiv_12626 crossref_primary_10_1128_JVI_03485_14 crossref_primary_10_36303_SAPJ_0135 crossref_primary_10_1177_2049936120920177 crossref_primary_10_1016_S2352_3018_17_30152_2 crossref_primary_10_1016_j_antiviral_2019_104552 crossref_primary_10_1097_MD_0000000000021661 crossref_primary_10_1128_AAC_01645_21 crossref_primary_10_1128_JVI_02451_14 crossref_primary_10_1002_jmv_24442 crossref_primary_10_1097_QAD_0000000000000461 crossref_primary_10_1007_s40506_013_0009_6 crossref_primary_10_1080_07391102_2020_1753577 crossref_primary_10_1007_s10096_019_03515_0 crossref_primary_10_1093_jac_dkw154 crossref_primary_10_1093_jac_dkx365 crossref_primary_10_1097_QAI_0000000000001525 crossref_primary_10_1177_0956462418815292 crossref_primary_10_1097_QAI_0000000000001649 crossref_primary_10_1186_s12977_022_00608_1 crossref_primary_10_1097_QAD_0000000000002533 crossref_primary_10_1128_AAC_00748_18 crossref_primary_10_1097_QAI_0000000000001883 crossref_primary_10_1186_s12981_016_0101_3 crossref_primary_10_1128_JVI_00695_14 crossref_primary_10_1038_s41598_018_22914_5 crossref_primary_10_7448_IAS_18_3_20177 crossref_primary_10_1007_s40265_013_0121_4 crossref_primary_10_1093_jac_dkv176 crossref_primary_10_1080_14656566_2020_1843635 crossref_primary_10_1093_jac_dkv296 crossref_primary_10_1128_AAC_01643_21 crossref_primary_10_1093_jac_dky443 crossref_primary_10_1177_0956462419829989 crossref_primary_10_1016_S2352_3018_23_00141_8 crossref_primary_10_1093_jac_dkx475 crossref_primary_10_1093_cid_ciw128 crossref_primary_10_1002_jia2_26523 crossref_primary_10_1186_s12981_016_0115_x crossref_primary_10_1128_CMR_00102_15 crossref_primary_10_3389_fmicb_2022_1051096 crossref_primary_10_1111_hiv_12675 crossref_primary_10_1093_cid_ciaa988 crossref_primary_10_1371_journal_pone_0240550 crossref_primary_10_1093_jac_dku199 crossref_primary_10_1111_hiv_13761 crossref_primary_10_1016_S1473_3099_15_00152_8 crossref_primary_10_1007_s00705_019_04463_y crossref_primary_10_1071_SH15210 crossref_primary_10_1097_QCO_0000000000000453 crossref_primary_10_1093_jac_dkw011 crossref_primary_10_1016_S2352_3018_20_30194_6 crossref_primary_10_1007_s40121_015_0071_0 crossref_primary_10_1097_QAD_0000000000002679 crossref_primary_10_1056_NEJMc1410930 crossref_primary_10_1080_17512433_2024_2308664 crossref_primary_10_1097_QAD_0000000000003520 crossref_primary_10_1111_hiv_12426 crossref_primary_10_1007_s40262_020_00898_8 crossref_primary_10_2146_ajhp140148 crossref_primary_10_1186_s12977_017_0360_7 crossref_primary_10_1128_JVI_01881_15 crossref_primary_10_3390_v13040594 crossref_primary_10_4102_sajhivmed_v18i1_776 crossref_primary_10_3389_fphar_2025_1625601 crossref_primary_10_1002_phar_2246 crossref_primary_10_1093_ofid_ofaf119 crossref_primary_10_1016_j_idc_2019_05_004 crossref_primary_10_1128_AAC_03131_15 crossref_primary_10_1007_s15006_014_3119_2 crossref_primary_10_7448_IAS_17_1_19034 crossref_primary_10_1097_QAD_0000000000001357 crossref_primary_10_1007_s40265_015_0446_2 crossref_primary_10_1097_QAD_0000000000001351 crossref_primary_10_1111_hiv_12692 crossref_primary_10_1371_journal_pone_0192627 crossref_primary_10_1002_prp2_598 crossref_primary_10_1310_hpj4902_184 crossref_primary_10_1128_aac_02038_21 crossref_primary_10_1093_jac_dkv029 crossref_primary_10_1002_jia2_25324 crossref_primary_10_1002_phar_1386 crossref_primary_10_1371_journal_pone_0224292 crossref_primary_10_1128_AAC_00611_20 crossref_primary_10_1038_s41598_023_51144_7 crossref_primary_10_1089_aid_2017_0205 |
| Cites_doi | 10.1128/AAC.00842-09 10.1086/503914 10.1016/S1473-3099(11)70249-3 10.1177/009286151104500309 10.1186/1742-4690-10-22 10.1056/NEJMoa0708978 10.1128/AAC.06170-11 10.1097/QAI.0b013e3181eb376b 10.1016/S0140-6736(12)60918-0 10.1016/S0140-6736(12)61853-4 10.1056/NEJMoa0708975 10.1016/j.antiviral.2011.12.008 10.1128/AAC.00073-11 10.1097/QAI.0b013e3181da1287 10.1128/AAC.00157-11 10.1016/S1473-3099(11)70196-7 10.1111/j.1365-2125.2012.04440.x 10.1016/S0140-6736(12)60917-9 10.1111/j.1464-410X.1985.tb06340.x 10.7448/IAS.15.6.18112 |
| ContentType | Journal Article |
| Contributor | Bartczak, Jennifer C Elliott, Julian Hedley James García, Juan González Buendia, Carlos J Beltran Legrand, Jean-Claude Katlama, Christine Henry, William K Galindo, Maria Jose Khoo, Saye H Sala, Bonaventura Clotet Conway, Brian Diaz, Ricardo S Kozal, Michael J Khanlou, Homayoon Barros, Carlos Horton, James Grinsztejn, Beatriz G J Nagimova, Firaya I Villanueva, Jaime-Federico Andrade Hodder, Sally Lynn Iglesia, Ma Angeles Castro Gogos, Charalambos Gathe, Jr, Joseph C Delfraissy, Jean-Francois Cassetti, Lidia I Johnson, Marc A Fourie, Jan Duiculescu, Dan Lupo, Sergio H Kegg, Stephen De Andrade Neto, Jose L Di Perri, Giovanni Lasso, Martin Felizarta, Franco Antonio B Kumar, Princy N Mingrone, Horacio Kulagin, Valery V Molina, Jean-Michel Cid, Juan Flores Madruga, Jose V R McDonald, Cheryl Kay Benetucci, Jorge A Casey, Kathleen K Brar, Indira Den Hollander, Jan G Hagins, Debbie P Bloch, Mark Moshkovich, Grigory F Feinberg, Judith De Truchis, Pierre Gulick, Peter G Hardy, William D Logue, Kenneth J Mikhaylov, Eduard V Blick, Gary Eron, Jr, Josep |
| Contributor_xml | – sequence: 1 givenname: Alejandro Elias Afani surname: Saud fullname: Saud, Alejandro Elias Afani – sequence: 2 givenname: Faïza surname: Ajana fullname: Ajana, Faïza – sequence: 3 givenname: Bisher surname: Akil fullname: Akil, Bisher – sequence: 4 givenname: Jaime-Federico Andrade surname: Villanueva fullname: Villanueva, Jaime-Federico Andrade – sequence: 5 givenname: Gregory M surname: Anstead fullname: Anstead, Gregory M – sequence: 6 givenname: Dénes surname: Bánhegyi fullname: Bánhegyi, Dénes – sequence: 7 givenname: Carlos surname: Barros fullname: Barros, Carlos – sequence: 8 givenname: Jennifer C surname: Bartczak fullname: Bartczak, Jennifer C – sequence: 9 givenname: Waldo H surname: Belloso fullname: Belloso, Waldo H – sequence: 10 givenname: Carlos J Beltran surname: Buendia fullname: Buendia, Carlos J Beltran – sequence: 11 givenname: Jorge A surname: Benetucci fullname: Benetucci, Jorge A – sequence: 12 givenname: Gary surname: Blick fullname: Blick, Gary – sequence: 13 givenname: Mark surname: Bloch fullname: Bloch, Mark – sequence: 14 givenname: Vicente Boix surname: Martínez fullname: Martínez, Vicente Boix – sequence: 15 givenname: Indira surname: Brar fullname: Brar, Indira – sequence: 16 givenname: Carlos Roberto Brites surname: Alves fullname: Alves, Carlos Roberto Brites – sequence: 17 givenname: Jeffrey H surname: Burack fullname: Burack, Jeffrey H – sequence: 18 givenname: Pedro E surname: Cahn fullname: Cahn, Pedro E – sequence: 19 givenname: Alfredo Cano surname: Sánchez fullname: Sánchez, Alfredo Cano – sequence: 20 givenname: Marcos M surname: Caseiro fullname: Caseiro, Marcos M – sequence: 21 givenname: Kathleen K surname: Casey fullname: Casey, Kathleen K – sequence: 22 givenname: Lidia I surname: Cassetti fullname: Cassetti, Lidia I – sequence: 23 givenname: Ma Angeles Castro surname: Iglesia fullname: Iglesia, Ma Angeles Castro – sequence: 24 givenname: Oksana E surname: Chernova fullname: Chernova, Oksana E – sequence: 25 givenname: Bonaventura Clotet surname: Sala fullname: Sala, Bonaventura Clotet – sequence: 26 givenname: Nathan surname: Clumeck fullname: Clumeck, Nathan – sequence: 27 givenname: Brian surname: Conway fullname: Conway, Brian – sequence: 28 givenname: Jose L surname: De Andrade Neto fullname: De Andrade Neto, Jose L – sequence: 29 givenname: Ignacio De los Santos surname: Gil fullname: Gil, Ignacio De los Santos – sequence: 30 givenname: Pierre surname: De Truchis fullname: De Truchis, Pierre – sequence: 31 givenname: Elisabet Deig surname: Comerma fullname: Comerma, Elisabet Deig – sequence: 32 givenname: Jean-Francois surname: Delfraissy fullname: Delfraissy, Jean-Francois – sequence: 33 givenname: Jan G surname: Den Hollander fullname: Den Hollander, Jan G – sequence: 34 givenname: Giovanni surname: Di Perri fullname: Di Perri, Giovanni – sequence: 35 givenname: Ricardo S surname: Diaz fullname: Diaz, Ricardo S – sequence: 36 givenname: Dan surname: Duiculescu fullname: Duiculescu, Dan – sequence: 37 givenname: Julian Hedley James surname: Elliott fullname: Elliott, Julian Hedley James – sequence: 38 givenname: Joseph J surname: Eron, Jr fullname: Eron, Jr, Joseph J – sequence: 39 givenname: Judith surname: Feinberg fullname: Feinberg, Judith – sequence: 40 givenname: Franco Antonio B surname: Felizarta fullname: Felizarta, Franco Antonio B – sequence: 41 givenname: Thomas M surname: File, Jr fullname: File, Jr, Thomas M – sequence: 42 givenname: Eric surname: Florence fullname: Florence, Eric – sequence: 43 givenname: Juan Flores surname: Cid fullname: Cid, Juan Flores – sequence: 44 givenname: Jan surname: Fourie fullname: Fourie, Jan – sequence: 45 givenname: Maria Jose surname: Galindo fullname: Galindo, Maria Jose – sequence: 46 givenname: Panagiotis surname: Gargalianos-Kakolyris fullname: Gargalianos-Kakolyris, Panagiotis – sequence: 47 givenname: Joseph C surname: Gathe, Jr fullname: Gathe, Jr, Joseph C – sequence: 48 givenname: Jade surname: Ghosn fullname: Ghosn, Jade – sequence: 49 givenname: Charalambos surname: Gogos fullname: Gogos, Charalambos – sequence: 50 givenname: Juan González surname: García fullname: García, Juan González – sequence: 51 givenname: Miguel Górgolas surname: Hernández-Mora fullname: Hernández-Mora, Miguel Górgolas – sequence: 52 givenname: Andrea surname: Gori fullname: Gori, Andrea – sequence: 53 givenname: Claudia surname: Goulston fullname: Goulston, Claudia – sequence: 54 givenname: Enrique Rafael surname: Granados-Reyes fullname: Granados-Reyes, Enrique Rafael – sequence: 55 givenname: Beatriz G J surname: Grinsztejn fullname: Grinsztejn, Beatriz G J – sequence: 56 givenname: Peter G surname: Gulick fullname: Gulick, Peter G – sequence: 57 givenname: Samir K surname: Gupta fullname: Gupta, Samir K – sequence: 58 givenname: Debbie P surname: Hagins fullname: Hagins, Debbie P – sequence: 59 givenname: William D surname: Hardy fullname: Hardy, William D – sequence: 60 givenname: Philip surname: Hay fullname: Hay, Philip – sequence: 61 givenname: William K surname: Henry fullname: Henry, William K – sequence: 62 givenname: Charles B surname: Hicks fullname: Hicks, Charles B – sequence: 63 givenname: Sally Lynn surname: Hodder fullname: Hodder, Sally Lynn – sequence: 64 givenname: James surname: Horton fullname: Horton, James – sequence: 65 givenname: Gregory surname: Huhn fullname: Huhn, Gregory – sequence: 66 givenname: Thomas T surname: Jefferson fullname: Jefferson, Thomas T – sequence: 67 givenname: Marc A surname: Johnson fullname: Johnson, Marc A – sequence: 68 givenname: Philip C surname: Johnson fullname: Johnson, Philip C – sequence: 69 givenname: Christine surname: Katlama fullname: Katlama, Christine – sequence: 70 givenname: Stephen surname: Kegg fullname: Kegg, Stephen – sequence: 71 givenname: Kamil M surname: Khafizov fullname: Khafizov, Kamil M – sequence: 72 givenname: Homayoon surname: Khanlou fullname: Khanlou, Homayoon – sequence: 73 givenname: Saye H surname: Khoo fullname: Khoo, Saye H – sequence: 74 givenname: Michael J surname: Kozal fullname: Kozal, Michael J – sequence: 75 givenname: Oleg A surname: Kozyrev fullname: Kozyrev, Oleg A – sequence: 76 givenname: Valery V surname: Kulagin fullname: Kulagin, Valery V – sequence: 77 givenname: Princy N surname: Kumar fullname: Kumar, Princy N – sequence: 78 givenname: Martin surname: Lasso fullname: Lasso, Martin – sequence: 79 givenname: Gulam surname: Latiff fullname: Latiff, Gulam – sequence: 80 givenname: Adriano surname: Lazzarin fullname: Lazzarin, Adriano – sequence: 81 givenname: Jean-Claude surname: Legrand fullname: Legrand, Jean-Claude – sequence: 82 givenname: Hsi-Hsun surname: Lin fullname: Lin, Hsi-Hsun – sequence: 83 givenname: Yu-Hui surname: Lin fullname: Lin, Yu-Hui – sequence: 84 givenname: Kenneth J surname: Logue fullname: Logue, Kenneth J – sequence: 85 givenname: Johannes Jurgens surname: Lombaard fullname: Lombaard, Johannes Jurgens – sequence: 86 givenname: Sergio H surname: Lupo fullname: Lupo, Sergio H – sequence: 87 givenname: Jose V R surname: Madruga fullname: Madruga, Jose V R – sequence: 88 givenname: M Del Mar surname: Masia fullname: Masia, M Del Mar – sequence: 89 givenname: Lewis H surname: McCurdy fullname: McCurdy, Lewis H – sequence: 90 givenname: Cheryl Kay surname: McDonald fullname: McDonald, Cheryl Kay – sequence: 91 givenname: Jeffery L surname: Meier fullname: Meier, Jeffery L – sequence: 92 givenname: Eduard V surname: Mikhaylov fullname: Mikhaylov, Eduard V – sequence: 93 givenname: Donna surname: Mildvan fullname: Mildvan, Donna – sequence: 94 givenname: Horacio surname: Mingrone fullname: Mingrone, Horacio – sequence: 95 givenname: Jean-Michel surname: Molina fullname: Molina, Jean-Michel – sequence: 96 givenname: Grigory F surname: Moshkovich fullname: Moshkovich, Grigory F – sequence: 97 givenname: Juan-Luis surname: Mosqueda-Gómez fullname: Mosqueda-Gómez, Juan-Luis – sequence: 98 givenname: Michel surname: Moutschen fullname: Moutschen, Michel – sequence: 99 givenname: Melissa D surname: Murphy fullname: Murphy, Melissa D – sequence: 100 givenname: Firaya I surname: Nagimova fullname: Nagimova, Firaya I |
| Copyright | 2013 Elsevier Ltd Elsevier Ltd Copyright © 2013 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Aug 24, 2013 |
| Copyright_xml | – notice: 2013 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2013 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Aug 24, 2013 |
| CorporateAuthor | on behalf of the extended SAILING Study Team extended SAILING Study Team |
| CorporateAuthor_xml | – name: on behalf of the extended SAILING Study Team – name: extended SAILING Study Team |
| DBID | FBQ AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PSYQQ Q9U S0X 7X8 7S9 L.6 |
| DOI | 10.1016/S0140-6736(13)61221-0 |
| DatabaseName | AGRIS CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials - QC Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Consumer Health Database (ProQuest) ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | ProQuest One Psychology AGRICOLA AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 708 |
| ExternalDocumentID | 3052581521 23830355 10_1016_S0140_6736_13_61221_0 US201500130343 S0140673613612210 1_s2_0_S0140673613612210 |
| Genre | Clinical Trial, Phase III Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | ViiV Healthcare. |
| GroupedDBID | --- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUFD ABUWG ACGFS ACGOD ACIEU ACIUM ACLOT ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AHHHB AHMBA AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UQL UV1 WOW X7M XAX XDU YYM Z5R ZMT ~HD .GJ 04C 3EH 3O- 3V. 41~ 88A 8WZ A6W AACTN AAEJM AAKAS AAQXK AAYOK ABDBF ABTAH ABWVN ACRPL ACRZS ACUHS ADMUD ADNMO ADZCM AFCTW AFFNX AFKWA AHQJS AJJEV AJOXV AKVCP ALIPV AMFUW ARTTT ASPBG AVWKF AZFZN D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H M0L M41 MVM OVD PKN Q~Q RIG SDF SV3 TEORI TH9 UHU WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 ABLVK ABYKQ AHPSJ AJBFU XFK ZA5 FBQ 9DU AAYXX ADXHL AFFHD AGQPQ AIGII CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI Q9U 7X8 PUEGO 7S9 L.6 |
| ID | FETCH-LOGICAL-c625t-1410c29c9d03ba1e5b10aca818e6ef25acbcc91ab5f07e13b629ee1f9f28c3923 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 455 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000323542400028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0140-6736 1474-547X |
| IngestDate | Sun Sep 28 09:39:34 EDT 2025 Sat Sep 27 17:57:54 EDT 2025 Sun Nov 09 13:47:19 EST 2025 Sat Sep 27 22:33:19 EDT 2025 Sat Nov 29 14:53:20 EST 2025 Mon Jul 21 06:05:57 EDT 2025 Sat Nov 29 07:25:00 EST 2025 Tue Nov 18 22:38:06 EST 2025 Thu Apr 03 09:45:37 EDT 2025 Fri Feb 23 02:34:36 EST 2024 Sun Feb 23 10:19:17 EST 2025 Tue Oct 14 19:30:59 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9893 |
| Language | English |
| License | Copyright © 2013 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c625t-1410c29c9d03ba1e5b10aca818e6ef25acbcc91ab5f07e13b629ee1f9f28c3923 |
| Notes | http://dx.doi.org/10.1016/S0140-6736(13)61221-0 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 23830355 |
| PQID | 1427311680 |
| PQPubID | 23462 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1678539026 proquest_miscellaneous_1566858956 proquest_miscellaneous_1439216759 proquest_miscellaneous_1428270487 proquest_journals_1427311680 pubmed_primary_23830355 crossref_citationtrail_10_1016_S0140_6736_13_61221_0 crossref_primary_10_1016_S0140_6736_13_61221_0 fao_agris_US201500130343 elsevier_sciencedirect_doi_10_1016_S0140_6736_13_61221_0 elsevier_clinicalkeyesjournals_1_s2_0_S0140673613612210 elsevier_clinicalkey_doi_10_1016_S0140_6736_13_61221_0 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-08-24 |
| PublicationDateYYYYMMDD | 2013-08-24 |
| PublicationDate_xml | – month: 08 year: 2013 text: 2013-08-24 day: 24 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2013 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Steigbigel, Cooper, Kumar (bib3) 2008; 359 DeJesus, Rockstroh, Henry (bib10) 2012; 379 Smith, Hammerstrom, Soon (bib23) 2011; 45 (bib22) May, 2001 Song, Borland, Chen (bib29) 2012; 3 Sax, DeJesus, Mills (bib2) 2012; 379 Hightower, Wang, Deanda (bib12) 2011; 55 Kastrup, Petersen, Bartram, Hansen (bib26) 1985; 57 Lennox, Dejesus, Berger (bib1) 2010; 55 Eron, Rockstroh, Reynes (bib5) 2011; 11 Song, Borland, Min (bib17) 2011; 55 Walmsley S, Antela A, Clumeck N, et al. Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results—SINGLE (ING114467). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, USA; Sept 9–12, 2012; abstr H-556b. Min, Song, Borland (bib13) 2010; 54 Hazuda, Miller, Nguyen, Zhao (bib7) 2007; 12 Cooper, Steigbigel, Gatell (bib9) 2008; 359 Raffi, Rachlis, Stellbrink (bib14) 2013; 381 Koteff, Borland, Chen (bib27) 2013; 75 Lepist EI, Murray BP, Tong L, Roy A, Bannister R, Ray A. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; Sept 17–20, 2011; abstr A1-1724. Liu, Shafer (bib20) 2006; 42 (bib21) Oct 18, 2007 Mesplède, Quashie, Osman (bib25) 2013; 10 McColl, Fransen, Gupta (bib8) 2007; 12 German, Warren, West, Hui, Kearney (bib6) 2010; 55 Nichols G, Mills A, Grossberg R, et al. Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor–based regimen: week 24 phase 3 results from VIKING-3. 11th International Congress on Drug Therapy in HIV Infection. Glasgow, UK; Nov 11–15, 2012; abstr O232. Margot, Hluhanich, Jones (bib24) 2012; 93 bib18 bib19 Molina, Lamarca, Andrade-Villanueva (bib4) 2012; 12 Garrido, Villacian, Zahonero (bib11) 2012; 56 Eron (10.1016/S0140-6736(13)61221-0_bib5) 2011; 11 Margot (10.1016/S0140-6736(13)61221-0_bib24) 2012; 93 McColl (10.1016/S0140-6736(13)61221-0_bib8) 2007; 12 Mesplède (10.1016/S0140-6736(13)61221-0_bib25) 2013; 10 Koteff (10.1016/S0140-6736(13)61221-0_bib27) 2013; 75 Song (10.1016/S0140-6736(13)61221-0_bib29) 2012; 3 10.1016/S0140-6736(13)61221-0_bib28 Kastrup (10.1016/S0140-6736(13)61221-0_bib26) 1985; 57 Song (10.1016/S0140-6736(13)61221-0_bib17) 2011; 55 Hightower (10.1016/S0140-6736(13)61221-0_bib12) 2011; 55 Smith (10.1016/S0140-6736(13)61221-0_bib23) 2011; 45 Steigbigel (10.1016/S0140-6736(13)61221-0_bib3) 2008; 359 Min (10.1016/S0140-6736(13)61221-0_bib13) 2010; 54 German (10.1016/S0140-6736(13)61221-0_bib6) 2010; 55 DeJesus (10.1016/S0140-6736(13)61221-0_bib10) 2012; 379 Garrido (10.1016/S0140-6736(13)61221-0_bib11) 2012; 56 Raffi (10.1016/S0140-6736(13)61221-0_bib14) 2013; 381 10.1016/S0140-6736(13)61221-0_bib15 Liu (10.1016/S0140-6736(13)61221-0_bib20) 2006; 42 Sax (10.1016/S0140-6736(13)61221-0_bib2) 2012; 379 Cooper (10.1016/S0140-6736(13)61221-0_bib9) 2008; 359 10.1016/S0140-6736(13)61221-0_bib16 Lennox (10.1016/S0140-6736(13)61221-0_bib1) 2010; 55 Molina (10.1016/S0140-6736(13)61221-0_bib4) 2012; 12 Hazuda (10.1016/S0140-6736(13)61221-0_bib7) 2007; 12 23830358 - Lancet. 2013 Aug 24;382(9893):664-6 Lancet. 2014 Jan 4;383(9911):30 |
| References_xml | – volume: 12 start-page: S11 year: 2007 ident: bib8 article-title: Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137) publication-title: Antivir Ther – ident: bib18 article-title: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults – volume: 379 start-page: 2439 year: 2012 end-page: 2448 ident: bib2 article-title: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks publication-title: Lancet – volume: 12 start-page: 27 year: 2012 end-page: 35 ident: bib4 article-title: Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study publication-title: Lancet Infect Dis – volume: 45 start-page: 291 year: 2011 end-page: 300 ident: bib23 article-title: A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions publication-title: Drug Inf J – reference: Walmsley S, Antela A, Clumeck N, et al. Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results—SINGLE (ING114467). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, USA; Sept 9–12, 2012; abstr H-556b. – volume: 55 start-page: 323 year: 2010 end-page: 329 ident: bib6 article-title: Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV publication-title: J Acquir Immune Defic Syndr – volume: 379 start-page: 2429 year: 2012 end-page: 2438 ident: bib10 article-title: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial publication-title: Lancet – year: Oct 18, 2007 ident: bib21 article-title: Guideline on the clinical development of medicinal products for the treatment of HIV infection (draft) – volume: 54 start-page: 254 year: 2010 end-page: 258 ident: bib13 article-title: Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers publication-title: Antimicrob Agents Chemother – volume: 359 start-page: 355 year: 2008 end-page: 365 ident: bib9 article-title: Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection publication-title: N Engl J Med – volume: 55 start-page: 4552 year: 2011 end-page: 4559 ident: bib12 article-title: Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes publication-title: Antimicrob Agents Chemother – reference: Lepist EI, Murray BP, Tong L, Roy A, Bannister R, Ray A. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; Sept 17–20, 2011; abstr A1-1724. – volume: 11 start-page: 907 year: 2011 end-page: 915 ident: bib5 article-title: Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial publication-title: Lancet Infect Dis – volume: 93 start-page: 288 year: 2012 end-page: 296 ident: bib24 article-title: In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4 publication-title: Antiviral Res – volume: 56 start-page: 2873 year: 2012 end-page: 2878 ident: bib11 article-title: Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens publication-title: Antimicrob Agents Chemother – reference: Nichols G, Mills A, Grossberg R, et al. Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor–based regimen: week 24 phase 3 results from VIKING-3. 11th International Congress on Drug Therapy in HIV Infection. Glasgow, UK; Nov 11–15, 2012; abstr O232. – volume: 42 start-page: 1608 year: 2006 end-page: 1618 ident: bib20 article-title: Web resources for HIV type 1 genotypic-resistance test interpretation publication-title: Clin Infect Dis – volume: 381 start-page: 735 year: 2013 end-page: 743 ident: bib14 article-title: Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study publication-title: Lancet – volume: 10 start-page: 22 year: 2013 ident: bib25 article-title: Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure publication-title: Retrovirology – volume: 75 start-page: 990 year: 2013 end-page: 996 ident: bib27 article-title: A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects publication-title: Br J Clin Pharmacol – ident: bib19 article-title: National Institutes of Allergy and Infectious Diseases, Division of Acquired Immunodeficiency Syndrome – volume: 12 start-page: S10 year: 2007 ident: bib7 article-title: Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a phase II study in patients with triple-class resistant HIV-1 infection publication-title: Antivir Ther – volume: 359 start-page: 339 year: 2008 end-page: 354 ident: bib3 article-title: Raltegravir with optimized background therapy for resistant HIV-1 infection publication-title: N Engl J Med – volume: 55 start-page: 39 year: 2010 end-page: 48 ident: bib1 article-title: Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses publication-title: J Acquir Immune Defic Syndr – year: May, 2001 ident: bib22 article-title: International Conference on Harmonisation (ICH). ICH Guidance for Industry: E 10 Choice of Control Group and Related Issues in Clinical Trials – volume: 57 start-page: 265 year: 1985 end-page: 268 ident: bib26 article-title: The effect of trimethoprim on serum creatinine publication-title: Br J Urol – volume: 55 start-page: 3517 year: 2011 end-page: 3521 ident: bib17 article-title: Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir publication-title: Antimicrob Agents Chemother – volume: 3 start-page: 9 year: 2012 ident: bib29 article-title: Metabolism and drug-drug interaction profile of dolutegravir (DTG, S/GSK1349572) [abstract O-07] publication-title: Rev Antivir Ther Infect Dis – volume: 12 start-page: S10 year: 2007 ident: 10.1016/S0140-6736(13)61221-0_bib7 article-title: Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a phase II study in patients with triple-class resistant HIV-1 infection publication-title: Antivir Ther – volume: 54 start-page: 254 year: 2010 ident: 10.1016/S0140-6736(13)61221-0_bib13 article-title: Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00842-09 – volume: 42 start-page: 1608 year: 2006 ident: 10.1016/S0140-6736(13)61221-0_bib20 article-title: Web resources for HIV type 1 genotypic-resistance test interpretation publication-title: Clin Infect Dis doi: 10.1086/503914 – volume: 12 start-page: 27 year: 2012 ident: 10.1016/S0140-6736(13)61221-0_bib4 article-title: Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(11)70249-3 – volume: 45 start-page: 291 year: 2011 ident: 10.1016/S0140-6736(13)61221-0_bib23 article-title: A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions publication-title: Drug Inf J doi: 10.1177/009286151104500309 – volume: 3 start-page: 9 year: 2012 ident: 10.1016/S0140-6736(13)61221-0_bib29 article-title: Metabolism and drug-drug interaction profile of dolutegravir (DTG, S/GSK1349572) [abstract O-07] publication-title: Rev Antivir Ther Infect Dis – volume: 10 start-page: 22 year: 2013 ident: 10.1016/S0140-6736(13)61221-0_bib25 article-title: Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure publication-title: Retrovirology doi: 10.1186/1742-4690-10-22 – ident: 10.1016/S0140-6736(13)61221-0_bib15 – volume: 359 start-page: 355 year: 2008 ident: 10.1016/S0140-6736(13)61221-0_bib9 article-title: Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection publication-title: N Engl J Med doi: 10.1056/NEJMoa0708978 – volume: 56 start-page: 2873 year: 2012 ident: 10.1016/S0140-6736(13)61221-0_bib11 article-title: Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.06170-11 – volume: 55 start-page: 323 year: 2010 ident: 10.1016/S0140-6736(13)61221-0_bib6 article-title: Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181eb376b – volume: 379 start-page: 2429 year: 2012 ident: 10.1016/S0140-6736(13)61221-0_bib10 publication-title: Lancet doi: 10.1016/S0140-6736(12)60918-0 – volume: 381 start-page: 735 year: 2013 ident: 10.1016/S0140-6736(13)61221-0_bib14 article-title: Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study publication-title: Lancet doi: 10.1016/S0140-6736(12)61853-4 – volume: 12 start-page: S11 year: 2007 ident: 10.1016/S0140-6736(13)61221-0_bib8 article-title: Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137) publication-title: Antivir Ther – volume: 359 start-page: 339 year: 2008 ident: 10.1016/S0140-6736(13)61221-0_bib3 article-title: Raltegravir with optimized background therapy for resistant HIV-1 infection publication-title: N Engl J Med doi: 10.1056/NEJMoa0708975 – volume: 93 start-page: 288 year: 2012 ident: 10.1016/S0140-6736(13)61221-0_bib24 article-title: In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4 publication-title: Antiviral Res doi: 10.1016/j.antiviral.2011.12.008 – ident: 10.1016/S0140-6736(13)61221-0_bib28 – volume: 55 start-page: 3517 year: 2011 ident: 10.1016/S0140-6736(13)61221-0_bib17 article-title: Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00073-11 – volume: 55 start-page: 39 year: 2010 ident: 10.1016/S0140-6736(13)61221-0_bib1 article-title: Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181da1287 – volume: 55 start-page: 4552 year: 2011 ident: 10.1016/S0140-6736(13)61221-0_bib12 article-title: Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00157-11 – volume: 11 start-page: 907 year: 2011 ident: 10.1016/S0140-6736(13)61221-0_bib5 article-title: Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(11)70196-7 – volume: 75 start-page: 990 year: 2013 ident: 10.1016/S0140-6736(13)61221-0_bib27 article-title: A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2012.04440.x – volume: 379 start-page: 2439 year: 2012 ident: 10.1016/S0140-6736(13)61221-0_bib2 article-title: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks publication-title: Lancet doi: 10.1016/S0140-6736(12)60917-9 – volume: 57 start-page: 265 year: 1985 ident: 10.1016/S0140-6736(13)61221-0_bib26 article-title: The effect of trimethoprim on serum creatinine publication-title: Br J Urol doi: 10.1111/j.1464-410X.1985.tb06340.x – ident: 10.1016/S0140-6736(13)61221-0_bib16 doi: 10.7448/IAS.15.6.18112 – reference: - Lancet. 2014 Jan 4;383(9911):30 – reference: 23830358 - Lancet. 2013 Aug 24;382(9893):664-6 |
| SSID | ssj0004605 |
| Score | 2.6008532 |
| Snippet | Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety,... Summary Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We... BACKGROUND: Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated... Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated... Background: Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated... |
| SourceID | proquest pubmed crossref fao elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 700 |
| SubjectTerms | Adult adults Antiretroviral agents diarrhea Double-Blind Method Drug Administration Schedule Drug dosages Drug resistance Drug Resistance, Viral Drug therapy drugs Female headache health services Heterocyclic Compounds, 3-Ring - administration & dosage Heterocyclic Compounds, 3-Ring - adverse effects HIV HIV Infections - drug therapy HIV Integrase Inhibitors - administration & dosage HIV Integrase Inhibitors - adverse effects HIV-1 Human immunodeficiency virus Human immunodeficiency virus 1 Humans Internal Medicine Male Middle Aged Mutation Patient safety patients Plasma Pyrrolidinones - administration & dosage Pyrrolidinones - adverse effects Raltegravir Potassium Respiratory tract respiratory tract diseases RNA RNA, Viral - metabolism Safety screening therapeutics Treatment Outcome Viral Load |
| Title | Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673613612210 https://www.clinicalkey.es/playcontent/1-s2.0-S0140673613612210 https://dx.doi.org/10.1016/S0140-6736(13)61221-0 https://www.ncbi.nlm.nih.gov/pubmed/23830355 https://www.proquest.com/docview/1427311680 https://www.proquest.com/docview/1428270487 https://www.proquest.com/docview/1439216759 https://www.proquest.com/docview/1566858956 https://www.proquest.com/docview/1678539026 |
| Volume | 382 |
| WOSCitedRecordID | wos000323542400028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M7P dateStart: 19920104 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0R dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0T dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7RV dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2M dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2O dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2P dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1db9Mw0KIbQrzwDSuMykg8gERYbCeNzQsaY2OVaKn2pb5ZtuNAxJSMpB3_jV_H2Umzl65D4uWk2L441l3uwz7fIfQ6VopqloJbooQNogxooZQVgbNetbDQECtfbCKZTPhsJqbthlvdhlUuZaIX1Glp3B75DolA0RIy5OHHi1-BqxrlTlfbEho9tOmyJDAfujdddS_Sh7hf3eDZOe4a3xD2FtQ8Ba_6Ot3Uy1R5vQXqNdHB_f9dwwN0r7VB8W7DNA_RLVs8QnfG7Sn7Y_Tns-NHl0XiMq-wi9tY1Lhy5-ptU15gIAgIy7nbkICewHYZk9N3uE1BUdsgL37kGmRGFRQKxCr22T5q7DZ_8eHo7AP-be1PHHEMTr_vcbddMNikMF2RlsCD7n1pudDnNtBgEcNTURaBCyGr8tIV3sPHu6Ovo8kX7BPlPkGnB_sne4dBW-MhMOB5zQMXZmqoMCINmVbExpqEyigwI-zQZjRWRhsjiNJxFiaWMD2kwlqSiYxyA7Yde4o2YF67hfDQZcZPmCacaxD_icgMB-dK2zhLbWRNH0VL6krTJkB3dTjO5YpIN8KkZwoZ9tH7Du2iyQByE8JwyTpyeb0VBLIEHXUTYrIK0datWKklkTWVYYPtkAnzqIDJO8zWcmoson-ZdAu4W6rvoFPk6TF1O2DuNJtFrI-2l2wsrz6h4-E-etV1Az-4gyZV2HLhx3CagG5I1o0B6hFwV8WaMeBr8JiDC79mDJA9ZiKkMOZZ81t2ZAJzFBYSx8_XL-QFukt9kRPQGdE22phXC_sS3TaX87yuBqiXHJ05OEs85AD5HhmgzU_7k-kRPI3DBp44SMcefvNwOvAC6S_Y-oKb |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1fb9MwELe2gYAX_sMKA4wEEpMIi52kiZEQmhij1dYKqR3am7GdC0RMyUjaTXwpPgCfjnP-7aXreNkDj7V9cRPf3e_OPt8R8iJQimsvRrdECXD8BNdCKRCOtV61AGwIVFVsIhyPo8ND8XmF_G7vwtiwylYnVoo6zo3dI99iPgItY_3IfX_807FVo-zpaltCo2aLPfh1ii5b-W64g-v7kvPdj9MPA6epKuAYtPVnjg1sNFwYEbueVgwCzVxlFAIX9CHhgTLaGMGUDhI3BObpPhcALBEJjwxaEx4-d5VcsXn1bAjhyJ0uuodZhdSf3RjamnSNr5i3iWYFRy_-PCxcTVR-vsVbId_urf_tm90mNxsbm27XQnGHrEB2l1wbNVEE98ifHStvNkvGSVpQG5cyL2lh4waapjSjyHAIBjO74YI9DnQZoePXtEmxUYKTZt9TjTqxcDKFsEGrbCYltZvbdDD88paeAvygfkQLKKsee5uHos2N02VxjjJmnxfnc30EjkaLH39leebYELkizW1hQTrZHu4Px59olQj4Pjm4lC_3gKzhvLBOaN9m_g89zaJII7yFIjEROo8agiQGH0yP-C03SdMkeLd1Ro7kgkg-5smKCaXbI286suM6w8lFBP2WVWV7fRcBRyIGX0QYLiKEslGbpWSy5NKtqS0x8ypSpIw6ysYyrC2-f5l0HaVJqm-ImfJgwu0Onz2t93yvRzZasZFnf6GTmR553nUjP9iDNJVBPq_GRDxE7AuXjcHVY-iOiyVj0JeKgkgE_SVjcNkDT7gcxzys1UC3TGhu44sEwaPlL_KMXB9MR_sSmXXvMbnBq4IuiI_-BlmbFXN4Qq6ak1laFk8rdUbJ18vWBX8BXYTXSg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELbagiouvKELBYwEEkiEje28jIRQ1aV0VVhVWop6M7bjQESVlGS3FX-tv46x8-hlu-XSA8e1PfEmHs83Y88DoRehlFSxFMwSyY0XZLAWUhruWe1VcQMNoXTFJuLJJDk85Psr6KyLhbFulZ1MdII6LbU9Ix-SAICWkCjxh1nrFrE_2vlw_NuzFaTsTWtXTqNhkT3z5xTMt_r9eARr_ZLSnY9ft3e9tsKAp0Hvn3nWyVFTrnnqMyWJCRXxpZYAYiYyGQ2lVlpzIlWY-bEhTEWUG0MyntFEg2bB4Lmr6FrMgIttlPo2WRST6dzrz6OHhtO-8RVhr0HFoGDRX4SLq5ksL9Z-HQru3Pqfv99tdLPVvfFWs1nuoBVT3EXrX1rvgnvobGT3oc2ecZJX2PqrzGtcWX-CtikvMDAigMTMHsRAj2f6TNHpG9ym3qiNlxc_cwWysvIKCXCCXZaTGttDb7w7_vYOnxrzCwcJrkztemyUDwZdHKYr0hL2nn1eWs7VkfEUWALwqygLz7rOVXlpCw7i6db483jyCbsEwffRwZV8uQdoDeY1GwhHtiJAzBRJEgWwF_NMJ2BUKhNmqQmMHqCg4yyh28Tvtv7IkVjg4UeYcAwp_AF625MdN5lPLiOIOrYVXVgvAJEAbL6MMF5EaOpWnNaCiJoKv6G2xIQ5UqBMespWY2w0wX-ZdAN2lpA_AEvFwZTakz97i88CNkCb3RYS53-h3z8D9LzvBn6wF2yyMOXcjUloDJgYLxsDq0fATOdLxoCNlYQJD6MlY2DZQ8Z9CmMeNiKhXyZQw-FFwvDR8hd5htZBBAjg1b3H6AZ1dV4ANoNNtDar5uYJuq5PZnldPXWSDaPvVy0K_gLJS9_I |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dolutegravir+versus+raltegravir+in+antiretroviral-experienced%2C+integrase-inhibitor-naive+adults+with+HIV%3A+week+48+results+from+the+randomised%2C+double-blind%2C+non-inferiority+SAILING+study&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Cahn%2C+Pedro&rft.au=Pozniak%2C+Anton+L&rft.au=Mingrone%2C+Horacio&rft.au=Shuldyakov%2C+Andrey&rft.date=2013-08-24&rft.issn=0140-6736&rft.volume=382&rft.issue=9893+p.700-708&rft.spage=700&rft.epage=708&rft_id=info:doi/10.1016%2FS0140-6736%2813%2961221-0&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673613X60404%2Fcov150h.gif |